3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Leukemia, Myeloid, Acute
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Hematologic Neoplasms
5
Myelodysplastic Syndromes
4
Tuberous Sclerosis
2
Recurrence
2
Primary Myelofibrosis
2
Myeloproliferative Disorders
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Epilepsy
2
Bronchiolitis Obliterans Syndrome
2
Thyroid Neoplasms
1
Solid Tumor
1
Sarcoma
1
Prostate Cancer Recurrent
1
Non-Malignant Neoplasm
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphoma
1
Lymphangioleiomyomatosis
1
Leukemia, Prolymphocytic
1
Leukemia, Plasma Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid
1
Interventions
Injections
6
Fluorodeoxyglucose F18
4
Cyclophosphamide
4
Bevacizumab
4
toripalimab
3
fludarabine
2
Specimen Handling
2
Nivolumab
2
zimberelimab
1
tumor-cells apoptosis factor, human
1
trametinib
1
tislelizumab
1
temsirolimus
1
spartalizumab
1
pembrolizumab
1
pazopanib
1
palbociclib
1
olaparib
1
lenvatinib
1
etoposide phosphate
1
enzalutamide
1
envafolimab
1
donafenib
1
disitamab vedotin
1
dabrafenib
1
cemiplimab
1
avelumab
1
atezolizumab
1
anlotinib
1
WW Domain-Containing Oxidoreductase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Solid Tumor
×
Sirolimus
×
Clear all
NCT04469530
2026-02-27
AflacST1903
Emory University
Phase 2
Recruiting
55 enrolled